The National Comprehensive Cancer Network NSCLC guidelines recommend capmatinib as either a first-line therapy or subsequent therapy option (preferred) for patients with metastatic NSCLC and MET exon 14 skipping mutations based on clinical trial data and FDA approval8. Here, MET is linked to non-small cell lung carcinoma.